Compugen (CGEN) SVP Levine Zurit Receives RSU & Option Grants (42,000)

What Happened Levine Zurit, Senior Vice President of Business Development at Compugen Ltd (CGEN), received two awards on 2026-07-29 totaling 42,000 units: 18,000 restricted stock units (RSUs) and 24,000 derivative option units. Both grants show an acquisition price of $0.00 on the Form 4, meaning these were equity awards (not open-market purchases or sales). This is a grant/award (transaction code A), not a sale — typically a compensation or retention award rather than a market-direction trade.

Key Details

• Transaction date: 2026-07-29; Form 4 filed 2026-07-30 (timely filing).
• Awards: 18,000 RSUs (F1) and 24,000 derivative option units (F2); total 42,000 units; reported acquisition price $0.00.
• Vesting: Both awards vest 25% on September 30, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued service.
• Shares owned after transaction: Not disclosed in the provided filing extract.
• Transaction code: A = Award/Grant. No 10b5-1 plan, tax-withholding, or late-filing indication noted in the filing excerpt.

Context These awards are compensation/retention awards that vest over time; RSUs convert into shares when they vest, and the derivative units (options) become exercisable per the vesting schedule. Because this is a grant (not a purchase or sale), it signals executive compensation/retention rather than an immediate trading view. Retail investors should note the vesting timeline if monitoring potential future insider selling or dilution when awards vest and are settled.